Company Background

Established in 2016, Prota Therapeutics is an Australian biotech company dedicated to developing and commercializing cutting-edge oral immunotherapy treatments. Our focus centers on leveraging proprietary food immunotherapy technology, developed under the leadership of Professor Mimi Tang’s research team, and exclusively licensed from the Murdoch Children’s Research Institute in Melbourne, Australia. Prota secured a Series A funding of AUD $15 million, led by OneVentures, a prominent Australian venture capital firm, and a subsequent Series A1 funding of US $21 million, spearheaded by SPRIM Global Investments, which underscores the industry’s recognition of our mission.

With headquarters in Melbourne, Australia, Prota Therapeutics is poised to advance its clinical program, strategically planning the initiation of a pivotal Phase 3 efficacy and safety study for our ground breaking PRT120 peanut allergy treatment. This signifies a crucial step forward in our commitment to addressing and revolutionizing the landscape of peanut allergy management.